Market Place
Sourcing Support
Everest Enters into Asset Purchase Agreement for Etripamil Spray
24 Mar 2026 //
PHARMIWEB
Everest Medicines Unveils 2030 Strategy as Directors
16 Dec 2025 //
PHARMIWEB
Everest Medicines Inks Commercialization & License Deals
15 Dec 2025 //
PHARMIWEB
Everest Medicines Acquires VIS-101, Rights For Eye Disease
31 Oct 2025 //
PHARMIWEB
Visara Assigns Its Exclusive License to Everest Med for VIS-101
29 Oct 2025 //
GLOBENEWSWIRE
Everest Medicines to Participate in September Investor Conference
25 Aug 2025 //
PR NEWSWIRE
Everest Medicines Gets Full Approval for NEFECON(R) in Taiwan
12 Aug 2025 //
PHARMAWEB
Everest Medicines` 2025 Interim Results Due August 29
11 Aug 2025 //
PR NEWSWIRE
Everest to Host Nephrology KOL Event on June 30
26 Jun 2025 //
GLOBENEWSWIRE
Everest Medicines Reports Positive Results at ERA-EDTA Congress
09 Jun 2025 //
PR NEWSWIRE
Everest Medicines to Announce 2024 Financial Results on March 26
25 Feb 2025 //
PR NEWSWIRE
Everest Announces Nefecon Pricing for IgA Nephropathy in China
02 Jan 2025 //
PHARMAWEB
Everest Medicines Announces Acceptance of NDA for VELSIPITY
19 Dec 2024 //
PHARMAWEB
Everest Medicine Accelerate Innovation in Renal Disease Leadership
12 Dec 2024 //
PHARMAWEB
Everest’s EVER001 Shows Promise in Primary Membranous Nephropathy
03 Dec 2024 //
PR NEWSWIRE
Everest Medicines to Hold Calls on EVER001 Data for Nephropathy
27 Nov 2024 //
PR NEWSWIRE
Everest Medicines Announces Interim Results for First Half of 2024
27 Aug 2024 //
PR NEWSWIRE
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
05 Aug 2024 //
PR NEWSWIRE
Calliditas Partner Everest Launches Nefecon In China
14 May 2024 //
PR NEWSWIRE
Everest Medicines Strengthens Management Team
17 Mar 2024 //
PR NEWSWIRE
Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
10 Mar 2024 //
PR NEWSWIRE
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28
05 Mar 2024 //
PR NEWSWIRE
Everest Medicines and Kezar Receive IND Approval from NMPA for PALIZADE Trial
26 Feb 2024 //
BUSINESSWIRE
Everest Medicines Announces Termination of Agreements with Providence
18 Feb 2024 //
PR NEWSWIRE
Calliditas Announces Nefecon to Significantly Slow Kidney Function Decline
20 Dec 2023 //
PR NEWSWIRE
Everest Medicines Announces Investigational NDA Acceptance of Zetomipzomib
03 Dec 2023 //
PR NEWSWIRE
Everest Medicines` Licensing Partner Pfizer Announces FDA Approves Etrasimod
15 Oct 2023 //
PR NEWSWIRE
Everest Medicines` Partner Calliditas Presents Data from NefIgArd Phase 3 Trial
04 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Calliditas Receives FDA Priority Review for Nefecon
20 Aug 2023 //
PR NEWSWIRE
Calliditas Announces Full Results From NefIgArd Phase 3 Trial published
17 Aug 2023 //
PR NEWSWIRE
Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
PR NEWSWIRE
Everest Medicines` Partner Calliditas Makes Data Presentations on Nefecon
20 Jun 2023 //
PR NEWSWIRE
Everest Medicines Announces Partnership with Shanghai Pharma Subsidiary
18 Apr 2023 //
PR NEWSWIRE
Everest Medicines partners with Guangdong Academy of Medical Sciences
24 Mar 2023 //
BIOSPECTRUM ASIA
Calliditas Reports Positive Topline Results from Phase 3 NefIgArd Trial
13 Mar 2023 //
PR NEWSWIRE
Everest Announces Silicon Valley Bank Developments Have Minimal Impact on Company
12 Mar 2023 //
PR NEWSWIRE
Everest Medicines to Hold New Corporate Strategy Online Conference Calls
29 Dec 2022 //
PR NEWSWIRE
Everest Medicines begins production at its new $129M+ mRNA vaccine
29 Dec 2022 //
ENDPTS
Everest Medicines Commences Operations at its mRNA Vaccine MFG Facility
27 Dec 2022 //
PRNEWSWIRE
Everest Medicines` Licensing Partner Pfizer Announces FDA and EMA
21 Dec 2022 //
PRNEWSWIRE
Everest Medicines Announces New mRNA Rabies Vaccine Program
14 Dec 2022 //
PRNEWSWIRE
Everest Medicines Announces Major Regulatory Updates in Taiwan for Nefecon
27 Nov 2022 //
PRNEWSWIRE
Everest Medicines Announces NDA Acceptance by China NMPA for Nefecon
14 Nov 2022 //
PRNEWSWIRE
Everest Announces Providence Reports Data from Phase 2 Immunization Trial
19 Oct 2022 //
PRNEWSWIRE
Everest climbs closer to booster market; A upstart snags funds to find drugs
19 Oct 2022 //
ENDPTS
Everest Medicines Announces Approval of XERAVA in Hong Kong
07 Oct 2022 //
PRNEWSWIRE
Everest receives China NMPA approval for Phase Ib trial of EVER001
26 Sep 2022 //
CLINICALTRIALSARENA
Everest appoints Gilead, COVID therapy vet as CEO
19 Sep 2022 //
FIERCEBIOTECH
Everest Medicines appoints new CEO to lead next stage of company growth
19 Sep 2022 //
BIOSPECTRUM
Blanchard abseils down from Everest, walking out as CEO with immediate effect
26 Aug 2022 //
FIERCEBIOTECH
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
25 Aug 2022 //
PRNEWSWIRE
Everest Medicines Announces Interim Results for First Half of 2022
24 Aug 2022 //
PRNEWSWIRE
Gilead to Acquire Remaining Worldwide Rights of Trodelvy
15 Aug 2022 //
BUSINESSWIRE
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy
15 Aug 2022 //
PRNEWSWIRE
Everest Medicines Announces Regulatory Update & Strategic Partnership for Xerava
12 Aug 2022 //
PRESS RELEASE
Everest Medicines Announces Strategic Partnership for Xerava in Taiwan
10 Aug 2022 //
PR NEWSWIRE
Everest Medicines Announces EC Grants Approval of Kinpeygo
17 Jul 2022 //
PRNEWSWIRE
Everest Medicines reaches its first peak in China with Trodelvy nod; & more
11 Jun 2022 //
ENDPTS
Everest Medicines Announces Approval of Trodelvy in China for 2L mTNBC
09 Jun 2022 //
PRNEWSWIRE
Gilead Sciences Announces Positive Results from PIII Study of Trodelvy
04 Jun 2022 //
PRNEWSWIRE
